Longhorn Vaccines and Diagnostics is a veteran-owned company, focused on molecular tool, assay and vaccine development. With an emphasis on innovation, the company’s goal is to improve molecular diagnostics to serve critical unmet needs in both the developed and developing world. Since 2006, Longhorn has been developing products in preparation for the occurrence of a pandemic. More than 15 years of continued investment and research has led the company to some of the largest breakthroughs in the testing space. Its unique diagnostic solutions thrive in a wide variety of environments, helping to diagnose and treat infectious diseases such as Influenza, SARS-CoV-2, and Mycobacterium Tuberculosis (MTB). The strength of Longhorn’s products has allowed it to scale exponentially in a matter of weeks. Whereas prior to March 2020, the company produced 50-100k tubes of PrimeStore MTM per month, during the height of the COVID-19 pandemic in the US, weekly shipments have exceeded 2 million tubes.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):